Lazar HL. Commentary: SGLT2 inhibitors reduce mortality and heart failure in patients with type 2 diabetes mellitus-is metabolic reprogramming the mechanism for these favorable outcomes? J Thorac Cardiovasc Surg 2021 Mar 5. pii: S0022-5223(21)00415.
PMID: 33812677